Zoetis Q3 2026: Stagnant Top Line, EPS Boosted by Cost Control

What happened

Zoetis reported third-quarter 2026 results that were in line with its own expectations, but the underlying trend remains worrisome as companion animal segment continued to face pressure, particularly in its osteoarthritis franchise, while livestock and diagnostics provided a partial offset. Management narrowed its full-year 2026 revenue guidance, implicitly acknowledging that revenue growth will likely fall short of earlier hopes, but simultaneously raised its adjusted EPS guidance, underscoring a pronounced reliance on expense discipline to protect profitability. This mirrors the pattern observed in 2025, when the company repeatedly trimmed revenue outlook while holding or increasing EPS targets through aggressive cost management—a strategy that can only paper over weak demand for so long. The lack of any clear stabilization or reacceleration in companion animal, especially the OA monoclonal antibodies that were supposed to be a major growth driver, suggests that the market's earlier recovery assumptions remain unfulfilled. Consequently, Zoetis continues to present a mixed picture: a high-quality business with robust cash generation but stalled top-line momentum, leaving the stock's risk-reward profile largely unchanged.

Implication

The raised EPS guidance may provide near-term support, but investors should not confuse cost-driven earnings beats with fundamental improvement—sustainable stock appreciation requires revenue growth. Continued pressure in companion animal, especially if OA mAb sales are still declining, will likely cap valuation multiple expansion and could lead to further de-rating if the trend extends into 2027. The offsetting growth in livestock and diagnostics demonstrates portfolio diversification, but these segments are not large or fast-growing enough to compensate for weakness in the core companion animal business. Given the thin margin of safety at current prices, investors should avoid adding to positions unless the stock approaches the $110 attractive entry level identified in the master report or until there is concrete evidence of OA franchise stabilization. For those holding the stock, the wait stance remains appropriate, with key monitoring points being quarterly OA mAb revenue trends and any guidance for 2027 that would clarify whether this is a temporary slowdown or a structural shift to lower growth.

Thesis delta

The Q3 2026 results reinforce the existing WAIT rating rather than altering it, as they confirm that top-line growth remains subdued and the companion animal recovery is not yet evident. The raised EPS guidance, while positive, is primarily a function of cost control and does not address the underlying revenue challenges that underpin the bear scenario. Accordingly, the investment thesis remains unchanged: hold positions but wait for either a better entry point or clear signs of OA mAb stabilization and revenue reacceleration before adding.